作者: Peter B. Bitterman , Vitaly A. Polunovsky
DOI: 10.1007/978-1-60327-271-1_12
关键词:
摘要: The limitations of contemporary cytotoxic therapy and the unveiling signaling networks that govern decision a cancer cell to propagate or die have spawned era targeted anticancer therapy. However, treatment patients with agents targeting specific oncoproteins frequently leads acquired resistance. What is next step in therapy? One robust approach drug discovery might be target few key pathways activated by oncogenes at vulnerable steps, i.e., nodal points where oncogenic converge. This concept embraces unfortunate reality several hundred genetic alterations – no one which obligatory for carcinogenesis are able usurp critical regulatory hubs converting cells from normal malignant. It also powerfully motivates search those components cellular machinery ubiquitous absolutely essential parts circuitry yet resilient enough tolerate perturbation. Two decades experimental data summarized here indicate eIF4F mediating initiation translation mRNA into protein an hub multiple thus bona fide candidate molecular discovery.